Trade group AusBiotech has called for a globally competitive and harmonised intellectual property system in its submission to the Productivity Commission’s Issues Paper on Australia’s Intellectual Property (IP) Arrangements.
Intellectual property is the fundamental source of protection for innovation. It is particularly important that local biotech and medtech innovation is not disadvantaged through a lack of harmonisation with other region’s IP systems. Ensuring that Australia has a globally competitive IP system is the key to our future health and wealth. Such a system will help:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze